Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: A randomised study

Thorax

Volumn 68, Issue 4, 2013, Pages 344-350

  Schuster, Antje ^a   Haliburn, Cynthia ^b   Döring, Gerd ^c   Goldman, Martin Harris ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Hartington Data Management and Statistics   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Forest Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPSILOMETER TEST; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POWDER INHALER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TASTE DISORDER; THROAT IRRITATION; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 84875215401     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202059     Document Type: Article

References (30)

1. Govan JRW, Deretic V. Microbial pathogens in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microb Rev 1996;60:539-74. (Pubitemid 26303478)
2. Fitzsimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
3. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100. (Pubitemid 34809519)
4. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87. (Pubitemid 32938876)
5. Döring G, Hoiby N, Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91. (Pubitemid 38987019)
6. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315.
7. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4:49-52.
8. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5. (Pubitemid 27225208)
9. Hodson ME, Gallagher CG, Govan Jr. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64.
10. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006;5:261-3. (Pubitemid 44824863)
11. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8. (Pubitemid 17092071)
12. Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis: Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. 3rd edn. London, UK, 2009.
13. Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med 2000;93:2-8. (Pubitemid 30311439)
14. Kettler LJ, Sawyer SM, Winefield HR, et al. Determinants of adherence in adults with cystic fibrosis. Thorax 2007;57:459-64.
15. Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43:S5-17.
16. Davies JC, Hall P, Francis J, et al. A dry powder formulation of colistimethate sodium is safe and well-tolerated in adults and children with CF. In: 18th Annual North American Cystic Fibrosis Conference, St Louis, Missouri, USA, 2004. Pediatr Pulmonol 2004;283:S27.
17. PH&T Pharma. Turbospin dry powder inhaler product brochure. http://www.phtpharma.com (accessed 18 oct 2012).
18. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34. (Pubitemid 13101554)
19. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42. (Pubitemid 24276863)
20. British Society for Antimicrobial Chemotherapy. Disc Diffusion Method for Antimicrobial Susceptibility Testing, Version 2.1, August 2001.
21. Quittner AL, Buu A, Messer MA, et al. Development and validation of the cystic fibrosis questionnaire in the USA: a health-related quality of life measure for cystic fibrosis. Chest 2005;128:2347-54. (Pubitemid 41507578)
22. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6. (Pubitemid 23170123)
23. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
24. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
25. Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865. (Pubitemid 15115129)
26. Pitt TL, Sparrow M, Warner M, et al. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-6. (Pubitemid 37094057)
27. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61.
28. Vu-Thien H, Moissenet D, Valcin M, et al. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis 1996;15:876-9. (Pubitemid 26421623)
29. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91-6.
30. Llor C, Bayona C, Hernandez S, et al. Comparison of adherence between twice and thrice daily regimens of oral amoxicillin/clavulanic acid. Respirology 2012;17: 687-92.